Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advanced-phase chronic myeloid leukemia.

Jorge Cortes1, Hagop Kantarjian

  • 1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Seminars in Hematology
|February 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adherence to BCR-ABL inhibitors: issues for CML therapy.

Clinical lymphoma, myeloma & leukemia·2012
Same author

Nilotinib-associated vascular events.

Clinical lymphoma, myeloma & leukemia·2012
Same author

How I treat newly diagnosed chronic phase CML.

Blood·2012
Same author

Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.

Cancer·2012
Same author

Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.

Clinical lymphoma, myeloma & leukemia·2012
Same author

A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.

Clinical lymphoma, myeloma & leukemia·2012
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Chronic myeloid leukemia (CML) advances through phases, with imatinib showing activity in accelerated (AP) and blastic phases (BP). New agents are crucial for improving outcomes in advanced CML.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myeloid leukemia (CML) typically progresses through distinct phases: chronic (CP), accelerated (AP), and blastic (BP).
  • Management of advanced CML phases (AP and BP) remains challenging, with limited efficacy of traditional therapies like interferon-alfa.
  • Variability in AP definitions complicates outcome comparisons and treatment strategies.

Purpose of the Study:

  • To review the efficacy of imatinib mesylate in advanced CML phases (AP and BP).
  • To explore emerging therapeutic agents and combination strategies for advanced CML.
  • To highlight the need for improved treatments to enhance long-term prognosis in advanced CML.

Main Methods:

  • Review of clinical trial data and published literature on imatinib efficacy in AP and BP CML.

Related Experiment Videos

  • Analysis of response rates (hematologic and cytogenetic) to imatinib in advanced CML.
  • Identification and summary of investigational agents and combination therapies for advanced CML.

    • Main Results:

    • Imatinib demonstrates significant activity in AP and BP CML, though less effective than in CP.
    • In AP, 82% hematologic response and 24% major cytogenetic remission (MCR) with imatinib; early MCR improves survival.
    • In BP, imatinib response rates are 21-36%, with limited duration; several novel agents are under investigation.

    Conclusions:

    • Imatinib offers therapeutic benefit in advanced CML phases but is inferior to CP treatment.
    • Early achievement of MCR in AP CML is associated with a survival advantage.
    • Further research into novel agents and combination therapies is essential for improving outcomes in advanced CML.